Health
Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…
-
Business21 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
General15 hours agoMan charged with murder after alleged assault victim dies in Hervey Bay
-
General16 hours agoGrieving Bunbury family outraged over plan to remove roadside memorial
-
General10 hours agoTaylor Swift breaks Adele’s record for most album sales in first week